Bio-Techne (BSP:T1CH34) Forward PE Ratio : 32.36 (As of Apr. 25, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Forward PE Ratio?

Bio-Techne's Forward PE Ratio for today is 32.36.

Bio-Techne's PE Ratio without NRI for today is 33.61.

Bio-Techne's PE Ratio for today is 46.03.

Bio-Techne Forward PE Ratio Historical Data

The historical data trend for Bio-Techne's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Forward PE Ratio Chart

Bio-Techne Annual Data

Trend

2020-12

2021-12

2022-12

2023-12

2024-04

Forward PE Ratio

61.35

59.52

41.32

31.45

33.11

Bio-Techne Quarterly Data
	2020-12	2021-03	2021-06	2021-09	2021-12	2022-03	2022-06	2022-09	2022-12	2023-03	2023-06	2023-09	2023-12	2024-03
Forward PE Ratio	61.35	55.56	60.98	67.11	59.52	50.25	38.76	33.44	41.32	33.33	31.85	35.59	31.45	34.97

Competitive Comparison of Bio-Techne's Forward PE Ratio

For the Biotechnology subindustry, Bio-Techne's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Techne's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Forward PE Ratio falls into.

Bio-Techne Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Bio-Techne (BSP:T1CH34) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Bio-Techne Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (BSP:T1CH34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

TECH:USA TE1:Germany

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (BSP:T1CH34) Headlines

No Headlines